国际简称:DIABETES METAB SYND 参考译名:糖尿病与代谢综合征-临床研究与评论
主要研究方向:ENDOCRINOLOGY & METABOLISM 非预警期刊 审稿周期:
《糖尿病与代谢综合征-临床研究与评论》(Diabetes & Metabolic Syndrome-clinical Research & Reviews)是一本由Elsevier出版的以ENDOCRINOLOGY & METABOLISM为研究特色的国际期刊,发表该领域相关的原创研究文章、评论文章和综述文章,及时报道该领域相关理论、实践和应用学科的最新发现,旨在促进该学科领域科学信息的快速交流。该期刊是一本未开放期刊,近三年没有被列入预警名单。
Diabetes&Metabolic Syndrome clinical Research&Reviews is an academic journal focusing on clinical research and review in the field of diabetes and metabolic syndrome. It aims to provide a platform for medical researchers, clinicians and public health experts worldwide to exchange and share the latest research results, clinical experience and treatment methods. As an international academic journal, it covers all aspects of diabetes and metabolic syndrome, including etiology, pathophysiology, diagnostic methods, drug treatment, non drug treatment, complication management and preventive measures. It not only focuses on the latest progress in basic research, but also focuses on the application and innovation in clinical practice. In terms of content, he mainly published original research papers, systematic reviews, case reports, clinical trials, meta-analysis, policy forums, educational reviews and other types of articles, covering various fields of diabetes and metabolic syndrome, providing readers with a comprehensive and in-depth understanding.
CiteScore | SJR | SNIP | CiteScore 指数 | ||||||||||||
22.9 | 1.313 | 1.459 |
|
名词解释:CiteScore 是衡量期刊所发表文献的平均受引用次数,是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年(含计算年度)的被引次数除以该期刊近四年发表的文献数。例如,2022年的 CiteScore 计算方法为:2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量 注:文献类型包括:文章、评论、会议论文、书籍章节和数据论文。
按JIF指标学科分区 | 收录子集 | 分区 | 排名 | 百分位 |
学科:ENDOCRINOLOGY & METABOLISM | ESCI | Q1 | 39 / 186 |
79.3% |
按JCI指标学科分区 | 收录子集 | 分区 | 排名 | 百分位 |
学科:ENDOCRINOLOGY & METABOLISM | ESCI | Q1 | 13 / 186 |
93.28% |